Cancer does not arrive on the day of exposure. It builds slowly, cell by cell, often over many years. That long latency between contact with a carcinogen and a diagnosis sits at the center of nearly every Roundup case, and it is one of the most misunderstood parts of the litigation.
The Short Answer
There is no single fixed number, but the human evidence points to a long latency — typically measured in years to decades, not months. In the Swedish case-control study by Eriksson and colleagues (2008), the association between glyphosate exposure and non-Hodgkin lymphoma was strongest when researchers applied a latency period greater than 10 years. That is consistent with how lymphomas tied to environmental carcinogens generally behave, developing over a window that is commonly described in the range of roughly 10 to 30 years.
What “Latency” Actually Means
In cancer science, latency is the interval between exposure to a cancer-causing agent and the clinical appearance of the disease. It is not a delay in the sense of a switch being flipped late. It reflects the fact that carcinogenesis is a multi-step process: genetic and cellular damage accumulates over time, the body’s repair and immune systems are repeatedly overcome, and only after that slow progression does a detectable cancer emerge.
For lymphomas — cancers of the immune system’s white blood cells — that process is rarely quick. The diagnoses central to this litigation include non-Hodgkin lymphoma and its subtypes such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Because these diseases develop gradually, a person can be exposed heavily in one decade and diagnosed in another, with no symptoms in between. The absence of symptoms during the gap is normal, not evidence that the exposure was harmless.
What the Studies Show About the Roundup-to-Lymphoma Timeline
The most direct evidence on timing comes from the case-control literature that helped drive the International Agency for Research on Cancer’s decision. In 2015, IARC — the cancer-research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans” (Group 2A) in Monograph Volume 112, with non-Hodgkin lymphoma identified as the cancer of concern. That classification rested in part on studies that examined not just whether people were exposed, but for how long and how long ago.
The Eriksson 2008 study, published in the International Journal of Cancer, is the clearest illustration of latency in action. In that population-based analysis of 910 lymphoma cases and 1,016 controls in Sweden, exposure to glyphosate was associated with non-Hodgkin lymphoma at an odds ratio of 2.02 (95% confidence interval 1.10–3.71). When the researchers restricted the analysis to a latency period of more than 10 years, the association did not fade — it strengthened, to an odds ratio of 2.26 (95% CI 1.16–4.40). In plain terms: the link looked stronger, not weaker, once enough time had passed for cancer to develop.
The broader body of evidence points the same direction when the analysis focuses on the most heavily exposed people. The Zhang 2019 meta-analysis, published in Mutation Research/Reviews in Mutation Research by researchers at UC Berkeley, the University of Washington, and the Icahn School of Medicine at Mount Sinai, pooled the human studies and reported that, using the highest-exposure groups, the risk of non-Hodgkin lymphoma was increased by 41% (meta-relative risk 1.41, 95% CI 1.13–1.75). Heavier, longer exposure — the kind that accrues over years — is where the signal is strongest.
Why a Long Latency Supports a Case — It Doesn’t Defeat One
Many people assume that a large gap between spraying Roundup and being diagnosed weakens the connection. The opposite is closer to the truth. Because reputable cancer research expects a long latency for lymphoma, a diagnosis that arrives years or decades after sustained exposure fits the recognized pattern of biological causation rather than contradicting it. This is why the Eriksson data showing a stronger association after 10-plus years matters so much: it is exactly what a genuine cause-and-effect relationship should look like.
Latency also helps explain why some cohort studies have reported weaker findings. Reviewers of the epidemiology have noted that when a study’s median follow-up is short, it may end before many long-latency cancers have had time to appear, which can dilute a real signal — a study-design limitation, not proof of safety. Our companion piece, what the human evidence on glyphosate and lymphoma actually shows, walks through how the case-control studies and the cohort data fit together.
Latency Is Not the Same as Your Legal Deadline
This is the distinction that costs people cases when they get it wrong. Latency is a medical concept — how long the cancer takes to develop. The statute of limitations is a legal deadline — how long you have to file suit. They are measured from different starting points, and confusing them leads people to give up when they may still have a claim.
In most states, the filing clock does not start on the day you were exposed. It starts, under what is called the discovery rule, when a person is diagnosed with a qualifying cancer and knew or reasonably should have known that it might be connected to Roundup. For the overwhelming majority of clients, that trigger date is the diagnosis — not the long-ago spraying. The specific deadline and how the discovery rule is applied vary by state, which is why our detailed guide on how long you have to file a Roundup lawsuit stresses acting quickly once you connect the diagnosis to the exposure.
“My Exposure Was Decades Ago — Am I Too Late?”
Not necessarily, and the reason ties the science and the law together. The same long latency that makes people doubt the connection is also why the legal system generally does not start the clock at exposure: it would be unfair to bar a claim before the injury even existed. A person who used Roundup heavily in the 1990s or 2000s and is diagnosed with non-Hodgkin lymphoma today has an exposure history that fits the recognized latency window, and a filing deadline that, in most states, runs from the recent diagnosis rather than the decades-old use.
What still has to be established is the exposure itself — the products used, the years, the frequency, and the setting. Because that history reaches back many years, documenting it takes care, and our guide on how to prove Roundup exposure explains the kinds of records, receipts, employment history, and witness accounts that build a credible timeline.
What This Means for a Case
Latency does not change who has a claim — that still turns on a qualifying diagnosis connected to a documented history of glyphosate exposure. What it changes is how the history is read: a gap of many years between spraying and diagnosis is normal, expected, and consistent with the science, not a red flag. Alex Alvarez, our Managing Partner and a Board Certified Civil Trial Lawyer, evaluates each person’s exposure timeline and diagnosis date together, because the interaction between the two determines both causation and the filing deadline. Herb Borroto, M.D., J.D., our Medical-Legal Expert, reviews the pathology personally to confirm the diagnosis is a lymphoma type supported by the established science before any strategy is set.
If you used Roundup years ago and have since been diagnosed — or if you have assumed too much time has passed to do anything about it — the right move is not to guess from a timeline in your head. Our overview of who qualifies for a Roundup lawsuit explains how the evaluation works and which diagnoses the litigation covers.
Frequently Asked Questions
How many years after Roundup exposure does non-Hodgkin lymphoma usually appear?
There is no single fixed number, but the human evidence points to a long latency measured in years to decades rather than months. In the Eriksson 2008 Swedish case-control study, the association between glyphosate exposure and non-Hodgkin lymphoma was strongest when researchers looked at a latency period greater than 10 years. That fits the broader pattern for lymphomas linked to environmental carcinogens, which commonly develop over roughly 10 to 30 years.
Does a long delay between exposure and diagnosis hurt my Roundup case?
Not by itself. A long delay is what cancer researchers expect, because carcinogenesis is a slow, multi-step process. Studies such as Eriksson 2008 actually found the glyphosate–lymphoma association was stronger, not weaker, when a latency period of more than 10 years was applied. The delay is consistent with biological causation. What matters legally is not how long ago the exposure was, but when the person knew or reasonably should have known their cancer was connected to Roundup.
My Roundup use was 20 or 30 years ago. Am I too late to file?
Possibly not. In most states the statute of limitations does not start counting from the date of exposure. Under the discovery rule it generally starts when a person is diagnosed with a qualifying cancer and knew or reasonably should have known it may be linked to Roundup. Because that date is usually the diagnosis, not the decades-earlier spraying, an old exposure does not automatically close the door. The deadline is state-specific, so it should be reviewed promptly with a lawyer.
Why do some studies not show a Roundup–lymphoma link if the latency is so long?
Follow-up time is part of the answer. Reviewers have noted that some cohort analyses had a median follow-up too short to capture cancers that take a decade or more to appear, which can dilute a long-latency signal. When researchers concentrate on the most heavily exposed people, the association strengthens: the Zhang 2019 meta-analysis reported a 41% increase in non-Hodgkin lymphoma risk in the highest glyphosate-exposure groups.
Bottom Line
The delay between using Roundup and being diagnosed with non-Hodgkin lymphoma is not a weakness in a case — it is how the disease works. The human evidence, from Eriksson’s latency analysis to the Zhang meta-analysis to IARC’s Group 2A classification, describes a cancer that develops over years to decades, with the link often looking stronger once enough time has passed. The mistake is to let that long biological timeline convince you the legal window has closed. In most states it has not, because the filing clock runs from diagnosis, not exposure.
Nothing here is a prediction about any particular case or about how the courts will rule, and past verdicts are never a promise of any future result. This article is general legal and medical information, not advice on your own facts, and it does not create an attorney-client relationship. If you or a family member used Roundup and were later diagnosed with Non-Hodgkin Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma — even if the exposure was many years ago — a free, confidential case review is the right next step.